Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 5, 2004, Pages 393-397

  Van Cott, Elizabeth M ^a,b   Laposata, Michael ^a,b   Hartnett, M Elizabeth ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Anticardiolipin antibodies; Antiphospholipid antibodies; Antithrombin; Factor V Leiden; Homocysteine; Hypercoagulable state; Lupus anticoagulant; Ocular thrombosis; Protein C; Protein S; Prothrombin G20210A

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; HOMOCYSTEINE; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN S; PROTHROMBIN; WARFARIN;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CHOROID CAPILLARY LAYER; CLINICAL ARTICLE; CONTROLLED STUDY; EYE DISEASE; FEMALE; GENE MUTATION; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; ISCHEMIC OPTIC NEUROPATHY; LABORATORY TEST; MALE; PRIORITY JOURNAL; RETINA VEIN OCCLUSION; STATISTICAL SIGNIFICANCE; THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; AGED; ANTIBODIES, ANTICARDIOLIPIN; CHILD; EYE DISEASES; FACTOR V; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; POINT MUTATION; PROTEIN C; PROTHROMBIN; THROMBOSIS;

EID: 3142588859     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000114442.59147.8d     Document Type: Article

References (33)

1. Glacet-Bernard A, Bayani N, Chretien P, Chchard C, Lelong F, Coscas G. Antiphospholipid antibodies in retinal vascular occlusions: A prospective study of 75 patients. Arch Ophthalmol 1994; 112:790-795.
2. Hartnett ME, Pruett RC, DaSilva KC, Burkart PT. Antiphospholipid antibody syndrome associated with microscotomata. Am J Ophthalmol 1994; 118:397-398.
3. Virgili G, Caucci S, Lanzetta P, Salati C, Menchini U. Retinal neovascularization in a case of macular branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 1997; 235:603-605.
4. Levine SR, Crofts JW, Lesser GR, Floberg J, Welch KM. Visual symptoms associated with the presence of a lupus anticoagulant. Ophthalmology 1988; 95:686-692.
5. Abu el-Asrar AM, Al-Momen AK, al-Amro S, Abdel Gader AG, Tabbara KF. Prothrombotic states associated with retinal venous occlusion in young adults. Int Ophthalmol 1996; 20:197-204.
6. Rumi V, Angelini L, Scaioli V, D'Angelo A, Besana C. Primary antiphospholipid syndrome and neurologic events. Pediatr Neurol 1993; 9:473-475.
7. Wenzler EM, Rademakers AJ, Boers GH, Cruysberg JR, Webers CA, Deutman AF. Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am J Ophthalmol 1993; 115:162-167.
8. Miserocchi E, Baltatzis S, Foster CS. Ocular features associated with anticardiolipin antibodies: a descriptive study. Am J Ophthalmol 2001; 131:451-456.
9. Leo-Kottler B, Klein R, Berg PA, Zrenner E. Ocular symptoms in association with antiphospholipid antibodies. Graefes Arch Clin Exp Ophthalmol 1998; 236:658-668.
10. Lahey JM, Tunc M, Kearney J, Modlinski B, Koo H, Johnson RN, Tanaka S. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years old. Ophthalmology 2002; 109:126-131.
11. Marcucci R, Bertini L, Giusti B, Brunelli T, Fedi S, Cellai AP, et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001; 86:772-776.
12. Greiner K, Hafner G, Dick B, Peetz D, Prellwitz W, Pfeiffer N. Retinal vascular occlusion and deficiencies in the protein C pathway. Am J Ophthalmol 1999; 128:69-74.
13. Tekeli O, Gursel E, Buyurgan H. Protein C, protein S and antithrombin III deficiencies in retinal vein occlusions. Acta Ophthalmol Scand 1999; 77:628-630.
14. Cobo-Soriano R, Sanchez-Ramon S, Aparicio MJ, Teijeiro MA, Vidal P, Suarez-Leon M, et al. Antiphospholipid antibodies and retinal thrombosis in patients without risk factors: a prospective case-control study. Am J Ophthalmol 1999; 128:725-732.
15. Boyd S, Owens D, Gin T, Bunce K, Sherafat H, Perry D, Hykin PG. Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol 2001; 85:1313-1315.
16. Larsson J, Hultberg B, Hillarp A. Hyperhomocysteinemia and the MTHFR C677T mutation in central retinal vein occlusion. Acta Ophthalmol Scand 2000; 78:340-343.
17. Larsson J, Hillarp A. The prothrombin gene G20210A mutation and the platelet glycoprotein IIIa polymorphism P1A2 in patients with central retinal vein occlusion. Thromb Res 1999; 96:323-327.
18. Gottlieb JL, Blice JP, Mestichelli B, Konkle BA, Benson WE. Activated protein C resistance, factor V Leiden and central retinal vein occlusion in young adults. Arch Ophthalmol 1998; 116:577-579.
19. Hodgkins PR, Perry DJ, Sawcer SJ, Keast-Butler J. Factor V and antithrombin gene mutations in patients with idiopathic central retinal vein occlusion. Eye 1995; 9:760-762.
20. Acheson JF, Gregson RMC, Merry P, Schulenberg WE. Vaso-occlusive retinopathy in the primary anti-phospholipid antibody syndrome. Eye 1991; 5:48-55.
21. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-3703.
22. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332:912-917.
23. Ravelli A, Martini A. Antiphospholipid antibody syndrome in pediatric patients. Rheum Dis Clin North Am 1997; 23:657-676.
24. Giorgi D, Gabrieli CB, Bonomo L. The clinico-ophthalmological spectrum of antiphospholipid syndrome. Ocul Immunol Inflamm 1998; 6:269-273.
25. Khamashta MS, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332:993-997.
26. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158:862-867.
27. Simioni P, Prandoni P, Burlina A, Tormene D, Sardella C, Ferrari V et al. Hyperhomocysteinemia and deep-vein thrombosis. A case control study. Thromb Haemost 1996; 76:883-886.
28. Larsson J, Hillarp A, Olafsdottir E, Bauer B. Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. Acta Ophthalmol Scand 1999; 77:634-637.
29. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42:1309-1311.
30. Petri M. Epidemiology of the anti-phospholipid antibody syndrome. J Autoimmun 2000; 15:145-151.
31. Orth DH, Patz A. Retinal branch vein occlusion. Surv Ophthalmol 1978; 22:357-376.
32. Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D. Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol 1982; 100:1132-1140.
33. Bowers DK, Finkelstein D, Wolff SM, Green WR. Branch retinal vein occlusion: a clinicopathologic case report. Retina 1987; 7:252-259.